Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25


Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.

Chen X, Hu P, Vaccaro N, Polidori D, Curtin CR, Stieltjes H, Sha S, Weiner S, Devineni D.

Clin Ther. 2015 Jul 1;37(7):1483-1492.e1. doi: 10.1016/j.clinthera.2015.04.015. Epub 2015 Jun 3.


Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age.

Cirillo I, Vaccaro N, Castaneda-Ruiz B, Redman R, Cossey V, Bradley JS, Allegaert K.

Antimicrob Agents Chemother. 2015 Aug;59(8):4742-9. doi: 10.1128/AAC.00485-15. Epub 2015 May 26.


Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.

Devineni D, Curtin CR, Marbury TC, Smith W, Vaccaro N, Wexler D, Vandebosch A, Rusch S, Stieltjes H, Wajs E.

Clin Ther. 2015 Mar 1;37(3):610-628.e4. doi: 10.1016/j.clinthera.2014.12.013. Epub 2015 Feb 3.


Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin.

Bernard A, Vaccaro N, Acharya M, Jiao J, Monbaliu J, De Vries R, Stieltjes H, Yu M, Tran N, Chien C.

Clin Pharmacol Drug Dev. 2015 Jan;4(1):63-73. doi: 10.1002/cpdd.132. Epub 2014 Jun 27.


Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on C-peptide kinetics.

Polidori D, Sha S, Heise T, Natarajan J, Artis E, Wang SS, Vaccaro N, Rothenberg P, Stirban A.

Clin Pharmacol Drug Dev. 2015 Jan;4(1):12-7. doi: 10.1002/cpdd.115. Epub 2014 May 28.


Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.

Devineni D, Vaccaro N, Polidori D, Stieltjes H, Wajs E.

Int J Clin Pharmacol Ther. 2015 Feb;53(2):129-38. doi: 10.5414/CP202218.


Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.

Sha S, Polidori D, Farrell K, Ghosh A, Natarajan J, Vaccaro N, Pinheiro J, Rothenberg P, Plum-Mörschel L.

Diabetes Obes Metab. 2015 Feb;17(2):188-97. doi: 10.1111/dom.12418. Epub 2015 Jan 5.


Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.

Devineni D, Vaccaro N, Murphy J, Curtin C, Mamidi RN, Weiner S, Wang SS, Ariyawansa J, Stieltjes H, Wajs E, Di Prospero NA, Rothenberg P.

Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28. doi: 10.5414/CP202158.


Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.

Devineni D, Manitpisitkul P, Vaccaro N, Bernard A, Skee D, Mamidi RN, Tian H, Weiner S, Stieltjes H, Sha S, Rothenberg P.

Int J Clin Pharmacol Ther. 2015 Jan;53(1):41-53. doi: 10.5414/CP202157.


Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing.

Inoue K, Shishido A, Vaccaro N, Jiao J, Stieltjes H, Bernard A, Yu M, Chien C.

Cancer Chemother Pharmacol. 2015 Jan;75(1):49-58. doi: 10.1007/s00280-014-2616-4. Epub 2014 Oct 25.


Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.

Stein P, Berg JK, Morrow L, Polidori D, Artis E, Rusch S, Vaccaro N, Devineni D.

Metabolism. 2014 Oct;63(10):1296-303. doi: 10.1016/j.metabol.2014.07.003. Epub 2014 Jul 9.


CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

Di Prospero NA, Artis E, Andrade-Gordon P, Johnson DL, Vaccaro N, Xi L, Rothenberg P.

Diabetes Obes Metab. 2014 Nov;16(11):1055-64. doi: 10.1111/dom.12309. Epub 2014 May 25.


Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.

Devineni D, Vaccaro N, Polidori D, Rusch S, Wajs E.

Clin Ther. 2014 May;36(5):698-710. doi: 10.1016/j.clinthera.2014.02.022. Epub 2014 Apr 13.


Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.

Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, Farrell K, Rothenberg P, Henry RR.

Diabetes Care. 2013 Aug;36(8):2154-61. doi: 10.2337/dc12-2391. Epub 2013 Feb 14.


Doripenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.

Samtani MN, Vaccaro N, Cirillo I, Matzke GR, Redman R, Nandy P.

ISRN Pharmacol. 2012;2012:782656. doi: 10.5402/2012/782656. Epub 2012 Jul 19.


Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes.

Katz LB, Gambale JJ, Rothenberg PL, Vanapalli SR, Vaccaro N, Xi L, Sarich TC, Stein PP.

Diabetes Obes Metab. 2012 Aug;14(8):709-16. doi: 10.1111/j.1463-1326.2012.01587.x. Epub 2012 Mar 14.


Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis.

Cirillo I, Vaccaro N, Redman R, Black PL, Kearns GL.

J Clin Pharmacol. 2012 Nov;52(11):1645-53. doi: 10.1177/0091270011427564. Epub 2011 Dec 14.


Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects.

Katz LB, Gambale JJ, Rothenberg PL, Vanapalli SR, Vaccaro N, Xi L, Polidori DC, Vets E, Sarich TC, Stein PP.

Clin Pharmacol Ther. 2011 Nov;90(5):685-92. doi: 10.1038/clpt.2011.169. Epub 2011 Oct 5.


Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.

Moore KT, Plotnikov AN, Thyssen A, Vaccaro N, Ariyawansa J, Burton PB.

J Cardiovasc Pharmacol. 2011 Dec;58(6):581-8. doi: 10.1097/FJC.0b013e31822f6c2b.


Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem.

Cirillo I, Vaccaro N, Balis D, Redman R, Matzke GR.

Antimicrob Agents Chemother. 2011 Mar;55(3):1187-93. doi: 10.1128/AAC.01063-10. Epub 2011 Jan 3.


Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.

Cirillo I, Vaccaro N, Turner K, Solanki B, Natarajan J, Redman R.

J Clin Pharmacol. 2009 Jul;49(7):798-806. doi: 10.1177/0091270009337012.


Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men.

Cirillo I, Mannens G, Janssen C, Vermeir M, Cuyckens F, Desai-Krieger D, Vaccaro N, Kao LM, Devineni D, Redman R, Turner K.

Antimicrob Agents Chemother. 2008 Oct;52(10):3478-83. doi: 10.1128/AAC.00424-08. Epub 2008 Jul 21.


Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.

McGowan T, Vaccaro NM, Beaver JS, Massarella J, Wolfson M.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1006-14. doi: 10.2215/CJN.05671207. Epub 2008 Apr 16.


Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive.

Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD, Leung AT.

J Clin Pharmacol. 2007 Apr;47(4):497-509.


Human herpesvirus-6B active infection associated with relapsing bilateral anterior optic neuritis.

Moschettini D, Franceschini R, Vaccaro NM, Cermelli C, Pezzini F, Balestrieri M, Cerase A, Bartalini S, Ulivelli M, Tosi GM, Donati D.

J Clin Virol. 2006 Dec;37(4):244-7. Epub 2006 Sep 26.


Supplemental Content

Loading ...
Support Center